Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Paxlovid could curb long-COVID symptoms in some patients

By Brian Buntz | November 9, 2022

Paxlovid

[Paxlovid image courtesy of James Heilman, MD, CC BY-SA 4.0, via Wikimedia Commons]

The antiviral nirmatrelvir in Paxlovid reduced the likelihood of people experiencing long-term symptoms after a COVID-19 infection, according to a recent preprint. Individuals who took Paxlovid within five days after infection were 26% less likely to have symptoms of long COVID 90 days after infection. 

The drug was associated with a reduced risk of long-COVID symptoms, more formally referred to as post-acute sequelae of COVID-19 (PASC). The benefits were found across patients regardless of whether they were unvaccinated, vaccinated or boosted. Additionally, the study authors found that Paxlovid reduced PASC risk whether patients were infected with COVID-19 for the first time or were reinfected with the virus. 

The study concluded that nirmatrelvir recipients were less likely to experience 10 of 12 long-COVID symptoms, including the following:

  1. Dysrhythmia.
  2. Ischemic heart disease.
  3. Deep vein thrombosis. 
  4. Pulmonary embolism. 
  5. Fatigue. 
  6. Liver disease.
  7. Acute kidney disease. 
  8. Muscle pain. 
  9. Neurocognitive impairment. 
  10. Shortness of breath. 

In addition to the reduced long-COVID symptom rates, the study also found that nirmatrelvir recipients had a lower risk of post-acute death and post-acute hospitalization. 

Consisting of the SARS-CoV-2 main protease inhibitor nirmatrelvir (PF-07321332) and the HIV-1 protease inhibitor and CYP3A inhibitor ritonavir, Paxlovid has become a staple COVID-19 treatment.  

Available under emergency use authorization (EUA), Paxlovid is indicated for vaccinated and unvaccinated individuals with a high risk of progression to severe COVID-19.

The drug is the first oral SARS-CoV-2 antiviral to win an EUA. 

The data from the study came from the Veterans Health Administration’s electronic medical records of 56,340 patients who were eligible for Paxlovid. Of that group, 9,217 took Paxlovid within five days of receiving a positive COVID-19 diagnosis. 

The average age of patients in the study was 65. 

While Paxlovid remains a popular drug, it has received negative attention for its association with a phenomenon known as Paxlovid rebound, in which COVID-19 symptoms initially ease but later reappear. Alternatively, Paxlovid rebound can lead patients to test positive for COVID-19 without experiencing symptoms. 


Filed Under: Infectious Disease
Tagged With: long-COVID symptoms
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE